Antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV transmission was first
approved by the US Food and Drug Administration in 2012. Despite correlations of …

Abstract Introduction Pre‐exposure prophylaxis (PrEP) is an important HIV prevention
option. Two randomized trials have provided efficacy evidence for long‐acting injectable …

Background Antiretroviral pre-exposure prophylaxis (PrEP) is clinically efficacious and
recommended for HIV prevention among people who inject drugs (PWID), but uptake …

Background: Delivery and use of HIV pre-exposure prophylaxis (PrEP) are suboptimal in the
United States. Previous reviews of barriers and facilitators have not used an implementation …

Introduction Novel mechanisms of service delivery are needed to expand access to pre-
exposure prophylaxis (PrEP) for HIV prevention. Providing PrEP directly through pharmacies …

Research is needed to determine targets for interventions to increase pre-exposure
prophylaxis (PrEP) uptake. The Information–Motivation–Behavioral Skills (IMB) model has …

Oral HIV pre-exposure prophylaxis (PrEP) is a highly effective pill that HIV-negative
individuals can take once daily to prevent HIV infection. Although PrEP is a private, user …

We reviewed the literature on the assessment of acceptability of HIV prevention and
treatment interventions and service delivery strategies. Following PRISMA guidelines, we …

Pre-Exposure Prophylaxis (PrEP) has been promoted among high-risk populations as an
effective HIV biomedical intervention. However, limited research is available on the …

Pre-exposure prophylaxis (PrEP) is a promising intervention to prevent HIV acquisition, with
benefits both to the individual and to population-level health. PrEP is an opportunity to …